Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 19/20 | 0.56 |
| ▸ | ABL1 | P00519 | 4/20 | 0.56 |
| ▸ | BCR | P11274 | 3/20 | 0.56 |
| ▸ | ABL2 | P42684 | 1/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3194620 | 0.85 | SRC (0.61) | SRCABL1BCR | |
| SCHEMBL3193839 | 0.82 | SRC (0.51) | SRCABL1BCRABL2PRKCQ | |
| SCHEMBL3193466 | 0.77 | EGFR (0.52) | — | |
| SCHEMBL3192149 | 0.76 | EGFR (0.50) | SRCPRKCQ | |
| SCHEMBL3180803 | 0.75 | MAP2K1 (0.54) | SRCPRKCQ | |
| SCHEMBL13480798 | 0.73 | SRC (0.52) | SRCABL1BCRABL2 | |
| SCHEMBL3184527 | 0.72 | EGFR (0.50) | PRKCQ | |
| SCHEMBL3189826 | 0.71 | KDR (0.42) | — | |
| SCHEMBL3190783 | 0.71 | EGFR (0.38) | — | |
| SCHEMBL3180849 | 0.71 | EGFR (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659284-B2 | Inhibitors of ATP-protein kinase; 7-(3-chloro-4-fluoro-phenylamino)-2-(4-pyrrolidin-1-ylmethyl-phenylamino)-thiazolo[4,5-b]pyridine-6-carbonitrile | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-09 | — | — | US | disclosed |
| US-7659284-B2 | Inhibitors of ATP-protein kinase; 7-(3-chloro-4-fluoro-phenylamino)-2-(4-pyrrolidin-1-ylmethyl-phenylamino)-thiazolo[4,5-b]pyridine-6-carbonitrile | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-09 | — | — | US | disclosed |
| US-7659284-B2 | Inhibitors of ATP-protein kinase; 7-(3-chloro-4-fluoro-phenylamino)-2-(4-pyrrolidin-1-ylmethyl-phenylamino)-thiazolo[4,5-b]pyridine-6-carbonitrile | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-09 | — | — | US | disclosed |
| EP-1789055-A2 | THIAZOLOPYRIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006031929-A2 | THIAZOLOPYRIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-03-23 | — | — | WO | disclosed |
| US-20060058341-A1 | Thiazolopyridine kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058341-A1 | Thiazolopyridine kinase inhibitors | PRKACA, PRKCE, MAP3K9 | SRC 423/4885ABL1 38/4885BCR 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.